DebateApoptosis is critical for drug response in vivo
References (18)
- et al.
Distinct mathematical behavior of apoptotic versus non-apoptotic tumor cell death
Int J Radiat Oncol Biol Phys
(1999) - et al.
Overexpression of Bcl-x(L) promotes chemotherapy resistance of mammary tumors in a syngeneic mouse model
Am J Pathol
(1999) - et al.
In vivo veritas: Bcl-2 and Bcl-XLmediate tumor cell resistance to chemotherapy
Drug Resist Updates
(2000) - et al.
Bcl-2 mediates chemoresistance in matched pairs of primary Eμ-myc lymphomas in vivo
Blood Cells Mol Dis
(2001) - et al.
Does tumor cell resistance to apoptosis affect the outcome of chemotherapy?
Drug Resist Updates
(2001) - et al.
Apoptosis, p53, and tumor cell sensitivity to anticancer agents
Cancer Res
(1999) - et al.
p53 status and the efficacy of cancer therapy in vivo
Science
(1994) - et al.
Apoptosis and therapy
J Pathol
(1999)
Cited by (70)
A pilot clinical trial of oral tetrahydrouridine/decitabine for noncytotoxic epigenetic therapy of chemoresistant lymphoid malignancies
2021, Seminars in HematologyCitation Excerpt :Salvage treatments for this patient population should address mechanisms of resistance to initial treatment. One mechanism-of-resistance is inactivation of the master regulators of apoptosis, p16/CDKN2A and TP53 [1-8], by mutation, deletion or epigenetics that confers resistance to multiple lines of therapy that share apoptosis (cytotoxicity) as a common final pathway of action (reviewed in [9-14]). Treatments that do not require the p53/p16-CDKN2A apoptosis-axis are hence needed.
Combination of the Pro-Apoptotic TRAIL-Receptor Antibody Mapatumumab With Ionizing Radiation Strongly Increases Long-Term Tumor Control Under Ambient and Hypoxic Conditions
2009, International Journal of Radiation Oncology Biology PhysicsCitation Excerpt :Instead, results of long-term assays employing local tumor control as primary endpoint might provide a more reliable surrogate parameter predicting clinical efficacy. In addition, the analysis of long-term outcomes after increasing apoptosis induction by any means is of crucial importance in radiation oncology because it has been generally questioned in how far modulations of apoptosis rates would improve treatment outcomes (20–22). Thus, based on the results of the initial efficacy testing, we decided to complement the results from our growth delay data by long-term tumor control assays.
Expression patterns and prognostic significance of inhibitor of apoptosis proteins in adenoid cystic carcinoma and pleomorphic adenoma of lachrymal gland
2009, Experimental Eye ResearchCitation Excerpt :Defects in the physiological pathway for apoptosis contribute to carcinogenesis. Moreover, aberrant inhibition of apoptosis interferes with normal cell regulation and promotes tumorigenesis (Borst et al., 2001; Reed, 2001; Schmitt and Lowe, 2001). Several anti-apoptotic genes, such as inhibitor of apoptosis protein (IAP) family members, take part in pathogenesis, progression and chemo- or radio-resistance of cancers (Reed, 2001).
The protozoan toxin climacostol inhibits growth and induces apoptosis of human tumor cell lines
2008, Chemico-Biological InteractionsCitation Excerpt :In order to explain the “anomalies” observed in PCD of A431 cells, it is useful to remark the increasing amount of evidence suggesting that some forms of drug-induced cell death cannot readily be classified as apoptosis, or necrosis, and are better associated with apoptosis-like, or necrosis-like PCD models [40]. Cell death can occur in an apoptosis-like programmed fashion, but in complete absence and/or independently of caspase activation [41–44]. Examples of apoptosis-like PCD are provided by ginkolic acids and sorbitol.
Emerging Significance of Ginsenosides as Potentially Reversal Agents of Chemoresistance in Cancer Therapy
2021, Frontiers in Pharmacology